Abstract Cannabinoids have long been used for their psychotropic and possible medical properties of symptom relief. In the past few years, a vast literature shows that cannabinoids are neuroprotective…
Condition: Parkinson’s Disease
The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders
Neurological Aspects of Medical Use of Cannabidiol
Abstract: Background: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential…
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Abstract Anecdotal evidence that cannabis preparations have medical benefits together with the discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated efforts to develop cannabinoid-based therapeutics. These efforts have been…
A systematic review of cannabidiol dosing in clinical populations
It is important to survey different population groups when researching the effects it has on medical conditions. This review discusses the doses applied to various population groups to better understand…
Self-Reported Efficacy of Cannabis and Other Complementary Medicine Modalities by Parkinson’s Disease Patients in Colorado
Abstract Introduction. Complementary and alternative medicine (CAM) is frequently used by Parkinson’s disease (PD) patients. We sought to provide information on CAM use and efficacy in PD patients in the…
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
Abstract Introduction: Parkinson’s disease (PD) has a progressive course and is characterized by the degeneration of dopaminergic neurons. Although no neuroprotective treatments for PD have been found to date, the endocannabinoid…
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series
What is known and objective: Cannabidiol (CBD) is the main non-psychotropic component of the Cannabis sativa plant. REM sleep behaviour disorder (RBD) is a parasomnia characterized by the loss of…
Activity of cannabis in relation to its delta’-trans-tetrahydro-cannabinol content
Conditions have been worked out for a reliable estimation of the cataleptic activity of delta’-trans-tetrahydrocannabinol (THC) after oral administration to mice, using the ring test over a period of 6…
Cannabidiol for the treatment of psychosis in Parkinson’s disease
The management of psychosis in Parkinson’s disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention. Previously an antipsychotic and neuroprotective…
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Objective: The aim of this review is to describe the historical development of research on cannabidiol. Method: This review was carried out on reports drawn from Medline, Web of Science…